Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Dupixent should never be used to treat an asthma attack. It does not work quickly enough to treat emergency symptoms. Always use your rescue inhaler as instructed by your doctor to treat symptoms ...

Information regarding our use of non-GAAP financial measures and ... reflecting the strength and durability of our key franchises, primarily, Dupixent, Libtayo, and EYLEA and EYLEA HD.

Obviously, Dupixent in COPD has a broader label ... Utilizing an on body delivery device, we believe this could ease the use and reduce some of the treatment burden along with the strong efficacy ...

We are also confident in the mid to long-term growth prospects of Sanofi, supported by ongoing launches, Dupixent (currently ... please see the first use of the word in the Pipeline update section.

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Q4: sales growth of 10.3% at CER1 and business EPS2 of €1.31 Pharma launches up ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.CTQLEHs_.js ...